Driehaus Capital Management LLC Purchases Shares of 542,828 Cellebrite DI Ltd. (NASDAQ:CLBT)

Driehaus Capital Management LLC acquired a new position in Cellebrite DI Ltd. (NASDAQ:CLBT) in the fourth quarter, according to the company in its most recent filing with the SEC. The firm acquired 542,828 shares of the company’s stock, valued at approximately $11,959,000. Driehaus Capital Management LLC owned 0.26% of Cellebrite DI at the end of the most recent quarter.

Other institutional investors also recently modified their holdings of the company. NewEdge Advisors LLC lifted its position in Cellebrite DI by 600.7% in the fourth quarter. NewEdge Advisors LLC now owns 3,910 shares of the company’s stock worth $86,000 after purchasing an additional 3,352 shares during the period. R Squared Ltd acquired a new position in shares of Cellebrite DI in the 4th quarter valued at $100,000. Polen Capital Management LLC bought a new position in shares of Cellebrite DI during the 4th quarter worth about $222,000. Victory Capital Management Inc. acquired a new stake in shares of Cellebrite DI during the 4th quarter valued at about $234,000. Finally, HighTower Advisors LLC bought a new stake in Cellebrite DI in the fourth quarter valued at about $274,000. Institutional investors and hedge funds own 45.88% of the company’s stock.

Analysts Set New Price Targets

CLBT has been the topic of a number of recent research reports. Lake Street Capital lifted their price objective on Cellebrite DI from $17.00 to $26.00 and gave the company a “buy” rating in a report on Friday, February 14th. JPMorgan Chase & Co. boosted their price target on Cellebrite DI from $24.00 to $28.00 and gave the company an “overweight” rating in a research note on Tuesday, February 11th. Finally, Needham & Company LLC reiterated a “buy” rating and set a $28.00 price objective on shares of Cellebrite DI in a research note on Wednesday, April 2nd. Seven investment analysts have rated the stock with a buy rating, Based on data from MarketBeat, the company currently has an average rating of “Buy” and an average target price of $23.43.

Cellebrite DI Stock Performance

Shares of NASDAQ:CLBT opened at $19.83 on Friday. Cellebrite DI Ltd. has a twelve month low of $10.25 and a twelve month high of $26.30. The firm has a market cap of $4.75 billion, a PE ratio of -14.27, a price-to-earnings-growth ratio of 4.27 and a beta of 1.44. The business has a fifty day moving average of $18.92 and a 200-day moving average of $20.22.

Cellebrite DI (NASDAQ:CLBT) last released its earnings results on Thursday, February 13th. The company reported $0.07 earnings per share for the quarter, missing analysts’ consensus estimates of $0.10 by ($0.03). Cellebrite DI had a positive return on equity of 58.70% and a negative net margin of 70.54%. On average, analysts anticipate that Cellebrite DI Ltd. will post 0.3 EPS for the current fiscal year.

About Cellebrite DI

Cellebrite DI Ltd. develops solutions for legally sanctioned investigations in Europe, the Middle East, Africa, the Americas, and the Asia-Pacific. The company's DI suite of solutions allows users to collect, review, analyze, and manage digital data across the investigative lifecycle with respect to legally sanctioned investigations used in various cases, including child exploitation, homicide, anti-terror, border control, sexual crimes, human trafficking, corporate security, cryptocurrency, and intellectual property theft.